Finance News Network discusses the successful Oventus ASX listing with Dr Chris Hart. View this great interview from 22 July 2016.
Dr Chris Hart also explains how the device has a significant point of difference, with a unique patented airway that is a paradigm shift in the treatment of sleep apnoea and has the ability to bypass nose, soft palate and tongue obstructions simultaneously.
“We’ve shown in our clinical trials that it has been very effective in patients with nasal obstruction in particular and also well in the severe range of sleep apnoea. At the moment the mouth guards, the O2Vent devices, are delivered through a network of dentists Australia-wide. We have 20 dentists at the moment delivering them across Australia in the capital cities and some regional areas, and we’re bringing about another 50 dentists online around Australia between now and the end of the year.”